Upcoming Events

View All Upcoming Events

News & Media

Superbugs - The threat is real.

Press Releases View All

2/20/2012

Cubist Pharmaceuticals to Present at February/March Investor Conferences
2/16/2012

Cubist Pharmaceuticals Appoints Alison Lawton to Board of Directors
2/9/2012

Cubist Receives CUBICIN Paragraph IV Notice Letter
1/19/2012

Cubist Pharmaceuticals Reports 2011 Fourth Quarter and Full Year Financial Results
1/10/2012

Cubist Pharmaceuticals and Hydra Biosciences Announce Plans to Begin Phase 1 Clinical Trial for Novel TRPA1 Modulator to Treat Acute Pain
1/9/2012

Cubist Announces Full Year 2011 Total CUBICIN Net Product Revenues of $735.5 Million, Up 18% Over 2010
1/4/2012

Cubist Pharmaceuticals and The New England Patriots Radio Network Honor Merrimack, New Hampshire, Science Teacher
12/13/2011

Cubist Announces First Patient Dosed in Pivotal Global Phase 3 Trial of CXA-201 for Complicated Intra-Abdominal Infections
12/12/2011

Cubist Pharmaceuticals Completes Acquisition of Adolor Corporation
12/7/2011

Cubist Pharmaceuticals Announces Results of Initial Tender Offer for Outstanding Shares of Adolor Corporation and Commencement of Subsequent Offering Period

Cubist in the News View All

Media Contact

At Cubist:

Francis McLoughlin
Director, Corporate Communications
(781) 860-8777
francis.mcloughlin@cubist.com